Wells Fargo
RNTX

Wells Fargo’s Rein Therapeutics RNTX Stock Holding History

Wells Fargo’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$26 – 7675
2026
Q1 		$26 Buy
+20
New +$25 ﹤0.01% 6742
2025
Q3 		– Sell
-1,688
Closed -$2.36K – 7482
2025
Q2 		$2.36K Buy
1,688
+1,686
+84,300% +$3.04K ﹤0.01% 6200
2025
Q1 		$4 Buy
+2
New +$4 ﹤0.01% 6906
2024
Q4 		– Sell
-9,544
Closed -$33.8K – 7238
2024
Q3 		$33.8K Buy
+9,544
New +$25.5K ﹤0.01% 5491
2024
Q2 		– Sell
-31
Closed -$206 – 7575
2024
Q1 		$206 Buy
31
+4
+15% +$19 ﹤0.01% 6489
2023
Q4 		$82 Buy
27
+3
+13% +$6 ﹤0.01% 6817
2023
Q3 		$36 Hold
24
– – ﹤0.01% 7015
2023
Q2 		$43 Buy
24
+1
+4% +$2 ﹤0.01% 7098
2023
Q1 		$29 Hold
23
– – ﹤0.01% 7278
2022
Q4 		$55 Buy
23
+1
+5% +$3 ﹤0.01% 6980
2022
Q3 		$0 Hold
22
– – ﹤0.01% 7543
2022
Q2 		$0 Buy
22
+2
+10% +$18 ﹤0.01% 7662
2022
Q1 		$0 Hold
20
– – ﹤0.01% 7997
2021
Q4 		$0 Hold
20
– – ﹤0.01% 7948
2021
Q3 		$0 Sell
20
-3
-13% -$66 ﹤0.01% 7650
2021
Q2 		$1K Buy
23
+2
+10% +$50 ﹤0.01% 6763
2021
Q1 		$1K Buy
21
+14
+200% +$480 ﹤0.01% 6781
2020
Q4 		$0 Hold
7
– – ﹤0.01% 7142
2020
Q3 		$0 Buy
7
+4
+133% +$94 ﹤0.01% 7035
2020
Q2 		$0 Hold
3
– – ﹤0.01% 6944
2020
Q1 		$0 Buy
+3
New +$36 ﹤0.01% 6938
2018
Q2 		– Sell
-42
Closed -$7K – 6629
2018
Q1 		$7K Hold
42
– – ﹤0.01% 6015
2017
Q4 		$9K Buy
42
+26
+163% +$6.23K ﹤0.01% 5954
2017
Q3 		$4K Buy
+16
New +$4.01K ﹤0.01% 6083

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Wells Fargo's RNTX Position: Q2 2026 in Review

Wells Fargo sold out of Rein Therapeutics (RNTX) in Q2 2026, closing a stake of 20 shares — an estimated $26 sold.

Wells Fargo first reported a position in RNTX in Q3 2017 and held it in 24 quarters. The position peaked at $33.8K in Q3 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Wells Fargo reported no remaining Rein Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 20 Rein Therapeutics shares in Q2 2026, an estimated $26.
  • Wells Fargo first reported a position in Rein Therapeutics in Q3 2017 and held it in 24 quarters.
  • Wells Fargo's Rein Therapeutics position peaked at $33.8K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.